Possible biological and translational significance of mast cells density in colorectal cancer

World Journal of Gastroenterology

Volumn , Issue 27, 2014, Pages 8910-8920

  Marech, Ilaria ^a   Ammendola, Michele ^b   Gadaleta, Claudia ^c   Zizzo, Nicola ^c   Oakley, Caroline ^a   Gadaleta, Cosmo Damiano ^a   Ranieri, Girolamo ^a  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^c UNIVERSITY OF BARI   (Italy)

Author keywords

Angiogenesis; C Kit receptor; C Kit receptor tyrosine kinase inhibitors; Colorectal cancer; Mast cell density; Proteinase activated receptor 2; Tryptase; Tryptase inhibitors; Tumor progression; Vascular endothelial growth factor

Indexed keywords

EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; GABEXATE; GRANULOCYTE COLONY STIMULATING FACTOR; IMATINIB; MASITINIB; MATRIX METALLOPROTEINASE; NAFAMSTAT MESILATE; PLATELET DERIVED GROWTH FACTOR; PROTEINASE ACTIVATED RECEPTOR 2; STEM CELL FACTOR RECEPTOR; TRYPTASE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; ANGIOGENIC PROTEIN;

ANGIOGENESIS; CANCER PROGNOSIS; CELL DENSITY; CELL INVASION; CELL PROLIFERATION; COLORECTAL CANCER; DISEASE FREE SURVIVAL; ELECTRON MICROSCOPY; EXTRACELLULAR MATRIX; HUMAN; IMMUNOHISTOCHEMISTRY; MAST CELL; METASTASIS; NONHUMAN; REVIEW; TUMOR GROWTH; ANIMAL; ANTAGONISTS AND INHIBITORS; COLORECTAL NEOPLASMS; DRUG DESIGN; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PROGNOSIS; SIGNAL TRANSDUCTION; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANGIOGENIC PROTEINS; ANIMALS; COLORECTAL NEOPLASMS; DRUG DESIGN; HUMANS; MAST CELLS; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; SIGNAL TRANSDUCTION;

EID: 84905371210     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i27.8910     Document Type: Review

References (110)

1. Nettleship T, Tay W. Rare forms of urticaria. Brit Med J 1869; 2: 323-330
2. Ehrlich P. Beiträge zur Kenntniss der granulirten Bindegewebszellen und der eosinophilen Leukocythen. Arch Anat Physiol (Leipzig) 1879; 3: 166-169
3. Ellis JM . Urticaria pigmentosa; a report of a case with autopsy. Arch Pathol (Chic) 1949; 48: 426-435 [PMID: 18149230]
4. Marone G, Spadaro G, Genovese A. Biology, diagnosis and therapy of mastocytosis. Chem Immunol 1995; 62: 1-21 [PMID: 7546277 DOI: 10.1159/000319293]
5. Horny HP, Sotlar K, Valent P. Mastocytosis: state of the art. Pathobiology 2007; 74: 121-132 [PMID: 17587883 DOI: 10.1159/000101711]
6. Orfao A, Garcia-Montero AC, Sanchez L, Escribano L. Recent advances in the understanding of mastocytosis: the role of KIT mutations. Br J Haematol 2007; 138: 12-30 [PMID: 17555444 DOI: 10.1111/j.1365-2141.2007.06619.x]
7. Shea-Donohue T, Stiltz J, Zhao A, Notari L. Mast cells. Curr Gastroenterol Rep 2010; 12: 349-357 [PMID: 20711694 DOI: 10.1007/s11894-010-0132-1]
8. Irani AM, Schwartz LB. Human mast cell heterogeneity. Allergy Proc 1994; 15: 303-308 [PMID: 7721078 DOI: 10.2500/108854194778816472]
9. Irani AA, Schechter NM, Craig SS, DeBlois G, Schwartz LB. Two types of human mast cells that have distinct neutral protease compositions. Proc Natl Acad Sci USA 1986; 83: 4464-4468 [PMID: 3520574 DOI: 10.1073/pnas.83.12.4464]
10. Marshall JS . Mast-cell responses to pathogens. Nat Rev Immunol 2004; 4: 787-799 [PMID: 15459670 DOI: 10.1038/nri1460]
11. Mangia A, Malfettone A, Rossi R, Paradiso A, Ranieri G, Simone G, Resta L. Tissue remodelling in breast cancer: human mast cell tryptase as an initiator of myofibroblast differentiation. Histopathology 2011; 58: 1096-1106 [PMID: 21707711 DOI: 10.1111/j.1365-2559.2011.03842.x]
12. Ranieri G, Ammendola M, Patruno R, Celano G, Zito FA, Montemurro S, Rella A, Di Lecce V, Gadaleta CD, Battista De Sarro G, Ribatti D. Tryptase-positive mast cells correlate with angiogenesis in early breast cancer patients. Int J Oncol 2009; 35: 115-120 [PMID: 19513558 DOI: 10.3892/ijo-00000319]
13. Ranieri G, Labriola A, Achille G, Florio G, Zito AF, Grammatica L, Paradiso A. Microvessel density, mast cell density and thymidine phosphorylase expression in oral squamous carcinoma. Int J Oncol 2002; 21: 1317-1323 [PMID: 12429983]
14. Ranieri G, Roccaro AM, Vacca A, Ribatti D. Thymidine phosphorylase (platelet-derived endothelial cell growth factor) as a target for capecitabine: from biology to the bedside. Recent Pat Anticancer Drug Discov 2006; 1: 171-183 [PMID: 18221035 DOI: 10.2174/157489206777442241]
15. Passantino L, Patruno R, Valerio P, Penna A, Mazzone F, Zito AF, Catalano V, Pellecchia A, Jirillo E, Ranieri G. Thymidine phosphorylase profiles in nonmalignant and malignant pancreatic tissue. Potential therapeutic role of capecitabine on tumoral and endothelial cells and tumor-infiltrating macrophages. Immunopharmacol Immunotoxicol 2005; 27: 95-107 [PMID: 15803863 DOI: 10.1081/IPH-51753]
16. Raica M, Cimpean AM, Ceausu R, Ribatti D, Gaje P. Interplay between mast cells and lymphatic vessels in different molecular types of breast cancer. Anticancer Res 2013; 33: 957-963 [PMID: 23482767]
17. Ribatti D, Nico B, Finato N, Crivellato E. Tryptase-positive mast cells and CD8-positive T cells in human endometrial cancer. Pathol Int 2011; 61: 442-444 [PMID: 21707849]
18. Nagata M, Shijubo N, Walls AF, Ichimiya S, Abe S, Sato N. Chymase-positive mast cells in small sized adenocarcinoma of the lung. Virchows Arch 2003; 443: 565-573 [PMID: 12827514 DOI: 10.1007/s00428-003-0842-y]
19. Horny HP, Greschniok A, Jordan JH, Menke DM, Valent P. Chymase expressing bone marrow mast cells in mastocytosis and myelodysplastic syndromes: an immunohistochemical and morphometric study. J Clin Pathol 2003; 56: 103-106 [PMID: 12560387 DOI: 10.1136/jcp.56.2.103]
20. Galli SJ, Kalesnikoff J, Grimbaldeston MA, Piliponsky AM, Williams CM, Tsai M. Mast cells as "tunable" effector and immunoregulatory cells: recent advances. Annu Rev Immunol 2005; 23: 749-786 [PMID: 15771585 DOI: 10.1146/annurev.immunol.21.120601.141025]
21. Oda K, Kitano H. A comprehensive map of the toll-like receptor signaling network. Mol Syst Biol 2006; 2: 2006.0015 [PMID: 16738560]
22. Coussens LM, Raymond WW, Bergers G, Laig-Webster M, Behrendtsen O, Werb Z, Caughey GH, Hanahan D. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 1999; 13: 1382-1397 [PMID: 10364156 DOI: 10.1101/gad.13.11.1382]
23. Nakayama T, Yao L, Tosato G. Mast cell-derived angiopoietin-1 plays a critical role in the growth of plasma cell tumors. J Clin Invest 2004; 114: 1317-1325 [PMID: 15520864 DOI: 10.1172/JCI22089]
24. Theoharides TC, Conti P. Mast cells: the Jekyll and Hyde of tumor growth. Trends Immunol 2004; 25: 235-241 [PMID: 15099563 DOI: 10.1016/j.it.2004.02.013]
25. Ribatti D, Crivellato E. Mast cells, angiogenesis and cancer. Adv Exp Med Biol 2011; 716: 270-288 [PMID: 21713661 DOI: 10.1007/978-1-4419-9533-9-14]
26. Ribatti D, Guidolin D, Marzullo A, Nico B, Annese T, Benagiano V, Crivellato E. Mast cells and angiogenesis in gastric carcinoma. Int J Exp Pathol 2010; 91: 350-356 [PMID: 20412338 DOI: 10.1111/j.1365-2613.2010.00714.x]
27. Ribatti D, Finato N, Crivellato E, Marzullo A, Mangieri D, Nico B, Vacca A, Beltrami CA. Neovascularization and mast cells with tryptase activity increase simultaneously with pathologic progression in human endometrial cancer. Am J Obstet Gynecol 2005; 193: 1961-1965 [PMID: 16325597 DOI: 10.1016/j.ajog.2005.04.055]
28. Ranieri G. Hot topic: targeting tumor angiogenesis: an update. Curr Med Chem 2012; 19: 937 [PMID: 22214460 DOI: 10.2174/092986712799320718]
29. Saponaro C, Malfettone A, Ranieri G, Danza K, Simone G, Paradiso A, Mangia A. VEGF, HIF-1α expression and MVD as an angiogenic network in familial breast cancer. PLoS One 2013; 8: e53070 [PMID: 23326384 DOI: 10.1371/journal.pone.0053070]
30. Ammendola M, Zuccalà V, Patruno R, Russo E, Luposella M, Amorosi A, Vescio G, Sammarco G, Montemurro S, De Sarro G, Sacco R, Ranieri G. Tryptase-positive mast cells and angiogenesis in keloids: a new possible post-surgical target for prevention. Updates Surg 2013; 65: 53-57 [PMID: 23117746 DOI: 10.1007/s13304-012-0183-y]
31. Ranieri G, Coviello M, Chiriatti A, Stea B, Montemurro S, Quaranta M, Dittadi R, Paradiso A. Vascular endothelial growth factor assessment in different blood fractions of gastrointestinal cancer patients and healthy controls. Oncol Rep 2004; 11: 435-439 [PMID: 14719080]
32. Ranieri G, Coviello M, Patruno R, Valerio P, Martino D, Milella P, Catalano V, Scotto F, De Ceglie A, Quaranta M, Ribatti D, Pellecchia A. Vascular endothelial growth factor concentrations in the plasma-activated platelets rich (P-APR) of healthy controls and colorectal cancer patients. Oncol Rep 2004; 12: 817-820 [PMID: 15375505]
33. Mangia A, Chiriatti A, Ranieri G, Abbate I, Coviello M, Simone G, Zito FA, Montemurro S, Rucci A, Di Leo A, Tommasi S, Berloco P, Xu JM, Paradiso A. H pylori status and angiogenesis factors in human gastric carcinoma. World J Gastroenterol 2006; 12: 5465-5472 [PMID: 17006982]
34. Ranieri G, Patruno R, Ruggieri E, Montemurro S, Valerio P, Ribatti D. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Curr Med Chem 2006; 13: 1845-1857 [PMID: 16842197 DOI: 10.2174/092986706777585059]
35. Miyazaki T, Okada N, Ishibashi K, Ogata K, Ohsawa T, Ishiguro T, Nakada H, Yokoyama M, Matsuki M, Kato H, Kuwano H, Ishida H. Clinical significance of plasma level of vascular endothelial growth factor-C in patients with colorectal cancer. Jpn J Clin Oncol 2008; 38: 839-843 [PMID: 18923001 DOI: 10.1093/jjco/hyn106]
36. Werther K, Christensen IJ, Nielsen HJ. The association between preoperative concentration of soluble vascular endothelial growth factor, perioperative blood transfusion, and survival in patients with primary colorectal cancer. Eur J Surg 2001; 167: 287-292 [PMID: 11354321 DOI: 10.1080/110241501300091480]
37. Ranieri G, Ruggieri E, Falco G, Zizzo N, Mattioli E, Zito AF, Patruno R, Gasparini G. Drug targets to pro-angiogenetic factors with special reference to primary peritoneal mesothelioma. Endocr Metab Immune Disord Drug Targets 2006; 6: 271-277 [PMID: 17017978 DOI: 10.2174/187153006778250028]
38. Hassan S, Kinoshita Y, Kawanami C, Kishi K, Matsushima Y, Ohashi A, Funasaka Y, Okada A, Maekawa T, He-Yao W, Chiba T. Expression of protooncogene c-kit and its ligand stem cell factor (SCF) in gastric carcinoma cell lines. Dig Dis Sci 1998; 43: 8-14 [PMID: 9508539 DOI: 10.1023/A:1018851415704]
39. Ribatti D, Ranieri G, Basile A, Azzariti A, Paradiso A, Vacca A. Tumor endothelial markers as a target in cancer. Expert Opin Ther Targets 2012; 16: 1215-1225 [PMID: 22978444 DOI: 10.1517/14728222.2012.725047]
40. Macfarlane SR, Seatter MJ, Kanke T, Hunter GD, Plevin R. Proteinase-activated receptors. Pharmacol Rev 2001; 53: 245-282 [PMID: 11356985]
41. Liu Y, Mueller BM. Protease-activated receptor-2 regulates vascular endothelial growth factor expression in MDA-MB-231 cells via MAPK pathways. Biochem Biophys Res Commun 2006; 344: 1263-1270 [PMID: 16650817 DOI: 10.1016/j.bbrc.2006.04.005]
42. Taipale J, Lohi J, Saarinen J, Kovanen PT, Keski-Oja J. Human mast cell chymase and leukocyte elastase release latent transforming growth factor-beta 1 from the extracellular matrix of cultured human epithelial and endothelial cells. J Biol Chem 1995; 270: 4689-4696 [PMID: 7876240 DOI: 10.1074/jbc.270.9.4689]
43. Gruber BL, Marchese MJ, Suzuki K, Schwartz LB, Okada Y, Nagase H, Ramamurthy NS. Synovial procollagenase activation by human mast cell tryptase dependence upon matrix metalloproteinase 3 activation. J Clin Invest 1989; 84: 1657-1662 [PMID: 2553780 DOI: 10.1172/JCI114344]
44. Stack MS, Johnson DA. Human mast cell tryptase activates single-chain urinary-type plasminogen activator (pro-urokinase). J Biol Chem 1994; 269: 9416-9419 [PMID: 8144524]
45. Blair RJ, Meng H, Marchese MJ, Ren S, Schwartz LB, Tonnesen MG, Gruber BL. Human mast cells stimulate vascular tube formation. Tryptase is a novel, potent angiogenic factor. J Clin Invest 1997; 99: 2691-2700 [PMID: 9169499 DOI: 10.1172/JCI119458]
46. Ribatti D, Ranieri G, Nico B, Benagiano V, Crivellato E. Tryptase and chymase are angiogenic in vivo in the chorioallantoic membrane assay. Int J Dev Biol 2011; 55: 99-102 [PMID: 21425085 DOI: 10.1387/ijdb.103138dr]
47. Tomita M, Matsuzaki Y, Edagawa M, Shimizu T, Hara M, Sekiya R, Onitsuka T. Association of mast cells with tumor angiogenesis in esophageal squamous cell carcinoma. Dis Esophagus 2001; 14: 135-138 [PMID: 11553224 DOI: 10.1046/j.1442-2050.2001.00171.x]
48. Ammendola M, Sacco R, Donato G, Zuccalà V, Russo E, Luposella M, Vescio G, Rizzuto A, Patruno R, De Sarro G, Montemurro S, Sammarco G, Ranieri G. Mast cell positivity to tryptase correlates with metastatic lymph nodes in gastrointestinal cancer patients treated surgically. Oncology 2013; 85: 111-116 [PMID: 23887206 DOI: 10.1159/000351145]
49. Acikalin MF, Oner U, Topc¸u I, Yaşar B, Kiper H, Colak E. Tumour angiogenesis and mast cell density in the prognostic assessment of colorectal carcinomas. Dig Liver Dis 2005; 37: 162-169 [PMID: 15888280 DOI: 10.1016/j.dld.2004.09.028]
50. Gulubova M, Vlaykova T. Prognostic significance of mast cell number and microvascular density for the survival of patients with primary colorectal cancer. J Gastroenterol Hepatol 2009; 24: 1265-1275 [PMID: 17645466 DOI: 10.1111/j.1440-1746.2007.05009.x]
51. Peng SH, Deng H, Yang JF, Xie PP, Li C, Li H, Feng DY. Significance and relationship between infiltrating inflammatory cell and tumor angiogenesis in hepatocellular carcinoma tissues. World J Gastroenterol 2005; 11: 6521-6524 [PMID: 16425427]
52. Esposito I, Menicagli M, Funel N, Bergmann F, Boggi U, Mosca F, Bevilacqua G, Campani D. Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma. J Clin Pathol 2004; 57: 630-636 [PMID: 15166270 DOI: 10.1136/jcp.2003.014498]
53. Tuna B, Yorukoglu K, Unlu M, Mungan MU, Kirkali Z. Association of mast cells with microvessel density in renal cell carcinomas. Eur Urol 2006; 50: 530-534 [PMID: 16426730 DOI: 10.1016/j.eururo.2005.12.040]
54. Ibaraki T, Muramatsu M, Takai S, Jin D, Maruyama H, Orino T, Katsumata T, Miyazaki M. The relationship of tryptase- and chymase-positive mast cells to angiogenesis in stage I non-small cell lung cancer. Eur J Cardiothorac Surg 2005; 28: 617-621 [PMID: 16125954 DOI: 10.1016/j.ejcts.2005.06.020]
55. Carlini MJ, Dalurzo MC, Lastiri JM, Smith DE, Vasallo BC, Puricelli LI, Lauría de Cidre LS. Mast cell phenotypes and microvessels in non-small cell lung cancer and its prognostic significance. Hum Pathol 2010; 41: 697-705 [PMID: 20040391 DOI: 10.1016/j.humpath.2009.04.029]
56. Ribatti D, Ennas MG, Vacca A, Ferreli F, Nico B, Orru S, Sirigu P. Tumor vascularity and tryptase-positive mast cells correlate with a poor prognosis in melanoma. Eur J Clin Invest 2003; 33: 420-425 [PMID: 12760367 DOI: 10.1046/j.1365-2362.2003.01152.x]
57. Benítez-Bribiesca L, Wong A, Utrera D, Castellanos E. The role of mast cell tryptase in neoangiogenesis of premalignant and malignant lesions of the uterine cervix. J Histochem Cytochem 2001; 49: 1061-1062 [PMID: 11457936 DOI: 10.1177/002215540104900816]
58. Ranieri G, Patruno R, Lionetti A, Di Summa A, Mattioli E, Bufo P, Pellecchia A, Ribatti D, Zizzo N. Endothelial area and microvascular density in a canine non-Hodgkin's lymphoma: an interspecies model of tumor angiogenesis. Leuk Lymphoma 2005; 46: 1639-1643 [PMID: 16236617 DOI: 10.1080/10428190500205150]
59. Nico B, Mangieri D, Crivellato E, Vacca A, Ribatti D. Mast cells contribute to vasculogenic mimicry in multiple myeloma. Stem Cells Dev 2008; 17: 19-22 [PMID: 18205547 DOI: 10.1089/scd.2007.0132]
60. Ribatti D, Molica S, Vacca A, Nico B, Crivellato E, Roccaro AM, Dammacco F. Tryptase-positive mast cells correlate positively with bone marrow angiogenesis in B-cell chronic lymphocytic leukemia. Leukemia 2003; 17: 1428-1430 [PMID: 12835741 DOI: 10.1038/sj.leu.2402970]
61. Ribatti D, Polimeno G, Vacca A, Marzullo A, Crivellato E, Nico B, Lucarelli G, Dammacco F. Correlation of bone marrow angiogenesis and mast cells with tryptase activity in myelodysplastic syndromes. Leukemia 2002; 16: 1680-1684 [PMID: 12200681 DOI: 10.1038/sj.leu.2402586]
62. Molica S, Vacca A, Crivellato E, Cuneo A, Ribatti D. Tryptase-positive mast cells predict clinical outcome of patients with early B-cell chronic lymphocytic leukemia. Eur J Haematol 2003; 71: 137-139 [PMID: 12890156 DOI: 10.1034/j.1600-0609.2003.00110.x]
63. Tomita M, Matsuzaki Y, Onitsuka T. Correlation between mast cells and survival rates in patients with pulmonary adenocarcinoma. Lung Cancer 1999; 26: 103-108 [PMID: 10568681 DOI: 10.1016/S0169-5002(99)00076-8]
64. Norrby K . Mast cells and angiogenesis. APMIS 2002; 110: 355-371 [PMID: 12076253 DOI: 10.1034/j.1600-0463.2002.100501.x]
65. Erba F, Fiorucci L, Pascarella S, Menegatti E, Ascenzi P, Ascoli F. Selective inhibition of human mast cell tryptase by gabexate mesylate, an antiproteinase drug. Biochem Pharmacol 2001; 61: 271-276 [PMID: 11172730 DOI: 10.1016/S0006-2952(00)00550-5]
66. Mori S, Itoh Y, Shinohata R, Sendo T, Oishi R, Nishibori M. Nafamostat mesilate is an extremely potent inhibitor of human tryptase. J Pharmacol Sci 2003; 92: 420-423 [PMID: 12939527 DOI: 10.1254/jphs.92.420]
67. Bai Y, Bandara G, Ching Chan E, Maric I, Simakova O, Bandara SN, Lu WP, Wise SC, Flynn DL, Metcalfe DD, Gilfillan AM, Wilson TM. Targeting the KIT activating switch control pocket: a novel mechanism to inhibit neoplastic mast cell proliferation and mast cell activation. Leukemia 2013; 27: 278-285 [PMID: 22907049 DOI: 10.1038/leu.2012.218]
68. Patruno R, Zizzo N, Zito AF, Catalano V, Valerio P, Pellecchia V, D'Errico E, Mazzone F, Ribatti D, Ranieri G. Microvascular density and endothelial area correlate with Ki-67 proliferative rate in the canine non-Hodgkin's lymphoma spontaneous model. Leuk Lymphoma 2006; 47: 1138-1143 [PMID: 16840207 DOI: 10.1080/10428190600565859]
69. Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 1957; 11: 359-377 [PMID: 13499785 DOI: 10.1038/bjc.1957.43]
70. Crivellato E, Nico B, Vacca A, Ribatti D. Ultrastructural analysis of mast cell recovery after secretion by piecemeal degranulation in B-cell non-Hodgkin's lymphoma. Leuk Lymphoma 2003; 44: 517-521 [PMID: 12688324 DOI: 10.1080/1042819021000047001]
71. Crivellato E, Ribatti D, Mallardi F, Beltrami CA. Granule changes of human and murine endocrine cells in the gastrointestinal epithelia are characteristic of piecemeal degranulation. Anat Rec 2002; 268: 353-359 [PMID: 12420282 DOI: 10.1002/ar.10149]
72. Ward SM, McLaren GJ, Sanders KM. Interstitial cells of Cajal in the deep muscular plexus mediate enteric motor neurotransmission in the mouse small intestine. J Physiol 2006; 573: 147-159 [PMID: 16513671 DOI: 10.1113/jphysiol.2006.105189]
73. Mikkelsen HB. Interstitial cells of Cajal, macrophages and mast cells in the gut musculature: morphology, distribution, spatial and possible functional interactions. J Cell Mol Med 2010; 14: 818-832 [PMID: 20132411 DOI: 10.1111/j.1582-4934.2010.01025.x]
74. Hiromatsu Y, Toda S. Mast cells and angiogenesis. Microsc Res Tech 2003; 60: 64-69 [PMID: 12500262 DOI: 10.1002/jemt.10244]
75. Gounaris E, Erdman SE, Restaino C, Gurish MF, Friend DS, Gounari F, Lee DM, Zhang G, Glickman JN, Shin K, Rao VP, Poutahidis T, Weissleder R, McNagny KM, Khazaie K. Mast cells are an essential hematopoietic component for polyp development. Proc Natl Acad Sci USA 2007; 104: 19977-19982 [PMID: 18077429 DOI: 10.1073/pnas.0704620104]
76. Heijmans J, Büller NV, Muncan V, van den Brink GR. Role of mast cells in colorectal cancer development, the jury is still out. Biochim Biophys Acta 2012; 1822: 9-13 [PMID: 21146606 DOI: 10.1016/j.bbadis.2010.12.001]
77. Chichlowski M, Westwood GS, Abraham SN, Hale LP. Role of mast cells in inflammatory bowel disease and inflammation-associated colorectal neoplasia in IL-10-deficient mice. PLoS One 2010; 5: e12220 [PMID: 20808919 DOI: 10.1371/journal.pone.0012220]
78. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001; 48: 526-535 [PMID: 11247898 DOI: 10.1136/gut.48.4.526]
79. Lachter J, Stein M, Lichtig C, Eidelman S, Munichor M. Mast cells in colorectal neoplasias and premalignant disorders. Dis Colon Rectum 1995; 38: 290-293 [PMID: 7882795 DOI: 10.1007/BF02055605]
80. Ranieri G, Ria R, Roccaro AM, Vacca A, Ribatti D. Development of vasculature targeting strategies for the treatment of chronic inflammatory diseases. Curr Drug Targets Inflamm Allergy 2005; 4: 13-22 [PMID: 15720230 DOI: 10.2174/1568010053622966]
81. Kashiwase Y, Inamura H, Morioka J, Igarashi Y, Kawai-Kowase K, Kurosawa M. Quantitative analysis of mast cells in benign and malignant colonic lesions: immunohistochemical study on formalin-fixed, paraffin-embedded tissues. Allergol Immunopathol (Madr) 2008; 36: 271-276 [PMID: 19080799 DOI: 10.1016/S0301-0546(08)75222-4]
82. Taweevisit M. The association of stromal mast cell response and tumor cell differentiation in colorectal cancer. J Med Assoc Thai 2006; 89 Suppl 3: S69-S73 [PMID: 17718271]
83. Xia Q, Ding Y, Wu XJ, Peng RQ, Zhou Q, Zeng J, Hou JH, Zhang X, Zeng YX, Zhang XS, Chen YB. Mast Cells in Adjacent Normal Colon Mucosa rather than Those in Invasive Margin are Related to Progression of Colon Cancer. Chin J Cancer Res 2011; 23: 276-282 [PMID: 23358806 DOI: 10.1007/s11670-011-0276-z]
84. Xia Q, Wu XJ, Zhou Q, Jing-Zeng JH, Pan ZZ, Zhang XS. No relationship between the distribution of mast cells and the survival of stage IIIB colon cancer patients. J Transl Med 2011; 9: 88 [PMID: 21651824 DOI: 10.1186/1479-5876-9-88]
85. Nielsen HJ, Hansen U, Christensen IJ, Reimert CM, Brünner N, Moesgaard F. Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue. J Pathol 1999; 189: 487-495 [PMID: 10629548]
86. Tan SY, Fan Y, Luo HS, Shen ZX, Guo Y, Zhao LJ. Prognostic significance of cell infiltrations of immunosurveillance in colorectal cancer. World J Gastroenterol 2005; 11: 1210-1214 [PMID: 15754407]
87. Elezoʇlu B, Tolunay S. The relationship between the stromal mast cell number, microvessel density, c-erbB-2 staining and survival and prognostic factors in colorectal carcinoma. Turk Patoloji Derg 2012; 28: 110-118 [PMID: 22627628 DOI: 10.5146/tjpath.2012.01109]
88. Fisher ER, Paik SM, Rockette H, Jones J, Caplan R, Fisher B. Prognostic significance of eosinophils and mast cells in rectal cancer: findings from the National Surgical Adjuvant Breast and Bowel Project (protocol R-01). Hum Pathol 1989; 20: 159-163 [PMID: 2562788 DOI: 10.1016/0046-8177(89)90180-9]
89. Yodavudh S, Tangjitgamol S, Puangsa-art S. Prognostic significance of microvessel density and mast cell density for the survival of Thai patients with primary colorectal cancer. J Med Assoc Thai 2008; 91: 723-732 [PMID: 18672639]
90. Malfettone A, Silvestris N, Saponaro C, Ranieri G, Russo A, Caruso S, Popescu O, Simone G, Paradiso A, Mangia A. High density of tryptase-positive mast cells in human colorectal cancer: a poor prognostic factor related to protease-activated receptor 2 expression. J Cell Mol Med 2013; 17: 1025-1037 [PMID: 23991686 DOI: 10.1111/jcmm.12073]
91. Song YX, Gao P, Wang ZN, Liang JW, Sun Z, Wang MX, Dong YL, Wang XF, Xu HM. Can the tumor deposits be counted as metastatic lymph nodes in the UICC TNM staging system for colorectal cancer? PLoS One 2012; 7: e34087 [PMID: 22461900 DOI: 10.1371/journal.pone.0034087]
92. Morikawa T, Tanaka N, Kuchiba A, Nosho K, Yamauchi M, Hornick JL, Swanson RS, Chan AT, Meyerhardt JA, Huttenhower C, Schrag D, Fuchs CS, Ogino S. Predictors of lymph node count in colorectal cancer resections: data from US nationwide prospective cohort studies. Arch Surg 2012; 147: 715-723 [PMID: 22508672 DOI: 10.1001/archsurg.2012.353]
93. Liu X, Cai H, Shi Y, Wang Y. Prognostic factors in patients with node-negative gastric cancer: a single center experience from China. J Gastrointest Surg 2012; 16: 1123-1127 [PMID: 22488657 DOI: 10.1007/s11605-012-1881-y]
94. Sjo OH, Merok MA, Svindland A, Nesbakken A. Prognostic impact of lymph node harvest and lymph node ratio in patients with colon cancer. Dis Colon Rectum 2012; 55: 307-315 [PMID: 22469798 DOI: 10.1097/DCR.0b013e3182423f62]
95. Ducroc R, Bontemps C, Marazova K, Devaud H, Darmoul D, Laburthe M. Trypsin is produced by and activates protease-activated receptor-2 in human cancer colon cells: evidence for new autocrine loop. Life Sci 2002; 70: 1359-1367 [PMID: 11883712 DOI: 10.1016/S0024-3205(01)01519-3]
96. Yoshii M, Jikuhara A, Mori S, Iwagaki H, Takahashi HK, Nishibori M, Tanaka N. Mast cell tryptase stimulates DLD-1 carcinoma through prostaglandin- and MAP kinase-dependent manners. J Pharmacol Sci 2005; 98: 450-458 [PMID: 16093613 DOI: 10.1254/jphs.FPJ05002X]
97. Jikuhara A, Yoshii M, Iwagaki H, Mori S, Nishibori M, Tanaka N. MAP kinase-mediated proliferation of DLD-1 carcinoma by the stimulation of protease-activated receptor 2. Life Sci 2003; 73: 2817-2829 [PMID: 14511767 DOI: 10.1016/S0024-3205(03)00702-1]
98. Sendo T, Sumimura T, Itoh Y, Goromaru T, Aki K, Yano T, Oike M, Ito Y, Mori S, Nishibori M, Oishi R. Involvement of proteinase-activated receptor-2 in mast cell tryptase-induced barrier dysfunction in bovine aortic endothelial cells. Cell Signal 2003; 15: 773-781 [PMID: 12781870 DOI: 10.1016/S0898-6568(03)00014-7]
99. Voltz JW, Weinman EJ, Shenolikar S. Expanding the role of NHERF, a PDZ-domain containing protein adapter, to growth regulation. Oncogene 2001; 20: 6309-6314 [PMID: 11607833 DOI: 10.1038/sj.onc.1204774]
100. Mangia A, Saponaro C, Malfettone A, Bisceglie D, Bellizzi A, Asselti M, Popescu O, Reshkin SJ, Paradiso A, Simone G. Involvement of nuclear NHERF1 in colorectal cancer progression. Oncol Rep 2012; 28: 889-894 [PMID: 22766563 DOI: 10.3892/or.2012.1895]
101. De Luisi A, Ferrucci A, Coluccia AM, Ria R, Moschetta M, de Luca E, Pieroni L, Maffia M, Urbani A, Di Pietro G, Guarini A, Ranieri G, Ditonno P, Berardi S, Caivano A, Basile A, Cascavilla N, Capalbo S, Quarta G, Dammacco F, Ribatti D, Vacca A. Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma. Clin Cancer Res 2011; 17: 1935-1946 [PMID: 21307145 DOI: 10.1158/1078-0432.CCR-10-2381]
102. Basile A, Moschetta M, Ditonno P, Ria R, Marech I, De Luisi A, Berardi S, Frassanito MA, Angelucci E, Derudas D, Specchia G, Curci P, Pavone V, Rossini B, Ribatti D, Bottazzi B, Mantovani A, Presta M, Dammacco F, Vacca A. Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell cross-talk in the bone marrow of multiple myeloma patients. J Pathol 2013; 229: 87-98 [PMID: 22847671 DOI: 10.1002/path.4081]
103. Ranieri G, Mammì M, Donato Di Paola E, Russo E, Gallelli L, Citraro R, Gadaleta CD, Marech I, Ammendola M, De Sarro G. Pazopanib a tyrosine kinase inhibitor with strong antiangiogenetic activity: a new treatment for metastatic soft tissue sarcoma. Crit Rev Oncol Hematol 2014; 89: 322-329 [PMID: 24041629]
104. Gnoni A, Marech I, Silvestris N, Vacca A, Lorusso V. Dasatinib: an anti-tumour agent via Src inhibition. Curr Drug Targets 2011; 12: 563-578 [PMID: 21226671 DOI: 10.2174/138945011794751591]
105. Yang XP, Li Y, Wang Y, Wang Y, Wang P. beta-Tryptase upregulates vascular endothelial growth factor expression via proteinase-activated receptor-2 and mitogen-activated protein kinase pathways in bone marrow stromal cells in acute myeloid leukemia. Leuk Lymphoma 2010; 51: 1550-1558 [PMID: 20578818 DOI: 10.3109/10428194.2010.496013]
106. Zhang H, Wu J, Meng L, Shou CC. Expression of vascular endothelial growth factor and its receptors KDR and Flt-1 in gastric cancer cells. World J Gastroenterol 2002; 8: 994-998 [PMID: 12439912]
107. Passantino L, Passantino G, Cianciotta A, Ribaud MR, Lo Presti G, Ranieri G, Perillo A. Expression of proto-oncogene C-kit and correlation with morphological evaluations in canine cutaneous mast cell tumors. Immunopharmacol Immunotoxicol 2008; 30: 609-621 [PMID: 18608529 DOI: 10.1080/08923970801949265]
108. Ranieri G, Gadaleta CD, Patruno R, Zizzo N, Daidone MG, Hansson MG, Paradiso A, Ribatti D. A model of study for human cancer: Spontaneous occurring tumors in dogs. Biological features and translation for new anticancer therapies. Crit Rev Oncol Hematol 2013; 88: 187-197 [PMID: 23561333 DOI: 10.1016/j.critrevonc.2013.03.005]
109. Ranieri G, Passantino L, Patruno R, Passantino G, Jirillo F, Catino A, Mattioli V, Gadaleta C, Ribatti D. The dog mast cell tumour as a model to study the relationship between angiogenesis, mast cell density and tumour malignancy. Oncol Rep 2003; 10: 1189-1193 [PMID: 12883679]
110. Ranieri G, Pantaleo M, Piccinno M, Roncetti M, Mutinati M, Marech I, Patruno R, Rizzo A, Sciorsci RL. Tyrosine kinase inhibitors (TKIs) in human and pet tumours with special reference to breast cancer: a comparative review. Crit Rev Oncol Hematol 2013; 88: 293-308 [PMID: 23768779]